Preview

Medical Immunology (Russia)

Advanced search

DEVELOPMENT OF A QUALIFICATION PROCEDURE FOR METHIONINE FORM OF INTERFERON ALFA-2b STANDARD TO CONFIRM ITS AUTHENTICITY BY MEANS OF A PEPTIDE MAPPING METHOD

https://doi.org/10.15789/1563-0625-2018-4-543-550

Abstract

Authenticity evaluation of proteins obtained with recombinant DNA technology is an important step in confirming efficacy and safety of the drugs based on them. One of the main ways to assess the authenticity is to compare molecular structure of the test and standard samples using the peptide mapping method with chromatographic separation of the products obtained by enzymatic degradation. Proper selection of a standard reference sample is essential in order to achieve reliable results. A standard sample of Interferon (CRS, Chemical Reference Substances) recommended by the European Agency for the Quality of Medicines for interferon alpha-2b substances containing N-terminal methionine is inappropriate, since the Interferon CRS sample doesn’t contain methionine. We present the results of development of qualification procedure for methionine form of Interferon alfa-2b industrial standard sample (ISS). The range of use for this ISS is authenticity confirmation for the methionine form of interferon alpha-2b substance using peptide mapping method with reverse-phase high-performance liquid chromatography (reverse-phase HPLC). The quality assessment was performed for all the parameters specified by the manufacturer of this candidate substance at the initial stage of qualification procedure, due to changed application area, and changed package size. Further, 30 peptide cards of the ISS candidate substance were obtained after pre-trypsinolysis of the protein followed by validated HPLC method with proven repeatability.

It was shown that the hydrolysis conditions, i.e., the choice of trypsin preparations, may significantly affect the peptide map profile. Therefore, a reference to specific manufacturer and the catalog number of the product should be provided in description of application conditions for the ISS proposed.

A set of eight reference peaks (peaks of comparison) has been justified, as based on evaluation of peptide maps and results of high-resolution mass spectrometry. The peak with maximally stable yield and intensity was selected as the main peak with an established absolute retention time. Two peaks with relative retention times were chosen as essential peaks for evaluation, i.e., the 1st peak containing N-terminal methionine, and the 2nd peak of highest molecular weight with an established amino acid sequence covering 11% of the studied interferon molecule.

We have also qualified ISS parameters expressed as absolute (minimum for one reference peak), and relative (for the remaining reference peaks) retention time periods. Authenticity of the ISS candidate was further confirmed by the peptide mapping method, as compared with interferon CRS reference standard. Their peak patterns proved to be near-similar, except of a peak with eluted peptide containing N-terminal methionine as revealed by high-resolution mass spectrometry

About the Authors

O. B. Ustinnikova
Testing Centre for Evaluation of Medicinal Immunobiological Products
Russian Federation

PhD (Biology), Head, Laboratory of MIBP Biochemistry,

127051, Moscow, Petrovsky blvrd, 8, bldg 2



E. O. Goloshchapova
Testing Centre for Evaluation of Medicinal Immunobiological Products
Russian Federation

Licensed Expert, Laboratory of MIBP Biochemistry,

Moscow



O. B. Runova
Testing Centre for Evaluation of Medicinal Immunobiological Products
Russian Federation

PhD (Chemistry), Main Licensed Expert, Laboratory of MIBP Biochemistry,

Moscow



M. G. Korotkov
Testing Centre for Evaluation of Medicinal Immunobiological Products
Russian Federation

PhD (Biology), Leading Expert, Laboratory of MIBP Biochemistry,

Moscow



R. A. Volkova
Testing Centre for Evaluation of Medicinal Immunobiological Products
Russian Federation

PhD, MD (Biology), Head, Laboratory of Molecular Biology and Genetic Testing,

Moscow



References

1. Бондарев В.П., Борисевич И.В., Волкова Р.А., Фадейкина О.В. Проблемы аттестации отраслевых стандартных образцов для контроля качества иммунобиологических лекарственных препаратов // Ведомости научного центра экспертизы средств медицинского применения, 2013. Т. 2. С. 28-32. [Bondarev V.P., Borisevich I.V.,Volkova R.A., Fadeykina O.V. The problems of certification of industry standard samples for quality control of immunobiological medicinal products. Vedomosti nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Bulletin of the Scientific Center for Expertise of Medical Applications, 2013, Vol. 2, pp. 28-32. (In Russ.)]

2. ГОСТ Р ИСО 5725-1-2002 [GOST R ISO 5725-1-2002].

3. Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы (от молекул до лекарств). М.: ГЭОТАРМедиа, 2005. 356 c. [Ershov F.I., Kiselev O.I. Interferons and their inducers (from molecules to drugs)]. Moscow: GEOTAR-Media, 2005. 356 p.

4. Климов В.И., Саканян Е.И., Волкова Р.А., Фадейкина О.В., Мовсесянц А.А., Лебединская Е.В., Шестакова А.П. Анализ потребностей в стандартных образцах, предназначенных для оценки качества биологических лекарственных средств // Биопрепараты. Профилактика, диагностика, лечение, 2017. Т. 17, № 2. С. 87-92. [Klimov V.I., Sakanyan E.I.,Volkova R.A., Fadeykina O.B., Movsesyants A.A., Lebedinskaya E.V., Shestakova A.P. Analysis of requirements for standard samples intended to assess the quality of biological medicinal products. Biopreparaty. Profilaktika, diagnostika, lechenie = Biopreparations. Prevention, Diagnosis, Treatment, 2017, Vol. 17, no. 2, pp. 87-92. (In Russ.)]

5. Соловьев В.Д., Бектемиров Т.А. Интерфероны в теории и практике медицины. М.: Медицина, 1981. 400 c. [Soloviev V.D., Bektemirov T.A. Interferons in theory and practice of medicine]. Moscow: Medicine, 1981. 400 p.

6. Устинникова О.Б., Рунова О.Б., Голощапова Е.О., Корсун Л.В. Теоретическое обоснование выбора субстанции интерферона альфа-2b для аттестации в качестве стандартного образца для оценки подлинности методом пептидного картирования // Биопрепараты. Профилактика, диагностика, лечение, 2016. Т. 16, № 3. С. 161-165. [Ustinnikova O.B., Runova O.B., Goloshchapova E.O., Korsun L.V. The theoretical substantiation of the choice of interferon alfa-2b substance for certification as a standard for authenticating peptide mapping. Biopreparaty. Profilaktika, diagnostika, lechenie = Biopreparations. Prevention, Diagnosis, Treatment, 2016, Vol. 16, no. 3, pp. 161-165. (In Russ.)]

7. Фармакопейная статья предприятия PN 003726/01-180515 [Pharmacopoeia article of the company PN 003726/01-180515].

8. Ben-Bassat A. Amino-terminal processing of proteins. Nature, 1987, pp. 315-326.

9. Dianzani F. Biological basis for the clinical use of interferon. Gut, 1993, Vol. 34, p. 76.

10. European Pharmacopoeia 9.0, 07/2015:1110 “Interferon alfa-2 concentrated solution”.

11. European Pharmacopoeia 9.0, 01/2010:20255 “Peptide mapping”.

12. Kamionka М. Engineering of therapeutic proteins production in Escherichia coli. Current Pharmaceutical Biotechnology, 2011, Vol. 12, pp. 268-274.


Review

For citations:


Ustinnikova O.B., Goloshchapova E.O., Runova O.B., Korotkov M.G., Volkova R.A. DEVELOPMENT OF A QUALIFICATION PROCEDURE FOR METHIONINE FORM OF INTERFERON ALFA-2b STANDARD TO CONFIRM ITS AUTHENTICITY BY MEANS OF A PEPTIDE MAPPING METHOD. Medical Immunology (Russia). 2018;20(4):543-550. (In Russ.) https://doi.org/10.15789/1563-0625-2018-4-543-550

Views: 1094


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)